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Abstract
Background:  The extent of angiogenesis is an important prognostic factor for colorectal
carcinoma, however, there are few studies concerning changes in angiogenesis with radiotherapy
(RTX). Our aim was to investigate changes in tumor angiogenesis influenced by radiotherapy to
assess the prognostic value of angiogenesis the microvessel density (MVD) in overall survival after
radiotherapy.
Methods: Tumor specimens were taken from 101 patients resected for rectal cancer. The patients
were divided into three groups according to the treatment they received before surgery (not
treated, a short course, or long course of RTX). Tumor specimens were paraffin-embedded and
immunohistochemistry was performed with primary antibody against CD-34 to count MVD.
Results: MVD was significantly lower in the group of patients treated with a long course of RTX
(p <0.025). The mean MVD for the long RTX group was 134.8; for the short RTX group – 192.5;
and for those not treated with RTX – 193.0. There were no significant statistical correlations
between MVD and age, sex, grade of tumor differentiation (G) and tumor size (T) in those
untreated with RTX. In long RTX group we found a significant prognostic rate for MVD when the
density cut off was near 130 with 92.3% sensitivity and 64.7% specificity. When the MVD was lower
than a cut off of 130, the survival period significantly increased (p = 0.001), the mortality rate is
significantly higher if the MVD is higher than 130 (microvessel/mm2) (1953.047; p = 0.002), if the
histological grade is moderate/poor (127.407; p = 0.013), if the tumor is T3/T4 (111.618; p = 0.014),
and if the patient is male (17.92; p = 0.034) adjusted by other variable in model.
Conclusion:  Our results show that a long course of radiotherapy significantly decreased
angiogenesis in rectal cancer tissue. MVD was found to be a favourable marker for tumor behaviour
during RTX and a predictor of overall survival after long course of RTX. Further investigations are
now needed to determine the changes in angiogenesis during a shorter course of RTX.
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Background
Colorectal cancer (CRC) is the third most common cancer
and the fourth most frequent cause of cancer deaths
worldwide [1]. CRC is a disease of the elderly, with only
5% of cases recorded in those younger than 40 years of age
[2]. CRC is commonly found to be rectal cancer (RC). The
main prognostic factors in RC are the size of the tumor
(T), lymph node metastases (N) and grade of tumor dif-
ferentiation (G) [3]. These factors are important for clini-
cal staging and treatment. Preoperative radiotherapy with
total mesorectal excision surgery improves local control,
but has no statistically-significant impact on overall sur-
vival [4]. An efficient adjuvant treatment is necessary to
further reduce the development of distant metastases and
to improve overall survival. By contrast, preoperative
chemoradiotherapy in terms of local control compared
with radiotherapy alone is now proven in locally
advanced rectal cancer, but overall survival is not yet mod-
ified by preoperative chemotherapy [5]. However little is
known about the effects of radiation on endothelial cell
behavior within these human tumors after radiotherapy
(RTX). It is conceivable that RTX could diminish both pro-
liferation and function of these endothelial cells (EC).
Common prognostic factors do not fully predict individ-
ual clinical outcomes especially among patients with
tumors of stage II and III. The response of clinically-iden-
tical tumors to the same treatment may be vastly different.
Therefore, to improve clinical care and to give an optimal
treatment, biological prognostic markers must be identi-
fied [6]. The relationship between tumor angiogenesis
with the grade of tumor differentiation, its metastatic
potential and prognosis for survival has been proven [1].
Formation of new blood vessels from the endothelium of
the existing vasculature is essential in angiogenesis [7].
The angiogenic process depends upon the balance
between many stimulatory and inhibitory factors. Pro-
angiogenic factors, such as vascular endothelial growth
factor (VEGF), bind to sites on endothelial cells that lead
to their proliferation. Microvessel density (MVD) is a sur-
rogate marker which expressly reflects tumor angiogenesis
and has been examined as a potential prognostic marker
in numerous tumors [8]. The aim of our study was to
investigate the changes in tumor angiogenesis under the
influence of different types of radiotherapy to assess the
prognostic value of angiogenesis (MVD) in the overall sur-
vival after radiotherapy.
Methods
Patients and tumor specimens
In this retrospective study, we assessed paraffin-embed-
ded specimens from tumors from 101 patients resected
for rectal cancer from January 2000 to December 2003.
This study included patients with resectable rectal carci-
noma. The exclusion criteria were a synchronous tumor or
tumors in another localisation in anamnesis, or emer-
gency surgery. The age of the patients was 69.4 ± 0.9 (rang-
ing from 36 to 87 years of age); for males, the mean age
was 68.7 ± 1.1 (n = 60), for females, mean age was 70.4 ±
1.5 (n = 41) years of age. All patients had confirmed rectal
adenocarcinomas by histopathology and were staged
according to the 5th edition of the American Joint Com-
mittee on Cancer (AJCC) Staging Manual [9]. All of the
patients underwent radical low anterior or abdominperi-
neal rectum resections. The patients were then divided
into three groups according to the radiotherapy they had
received before surgery. The first group (n = 57) only
underwent surgery (no RTX), the second (n = 16) had 25
Gy short course radiotherapy (short RTX) and surgery, the
third group (n = 28) had 48 – 52 Gy long course radio-
therapy (long RTX) and surgery. The no RTX and short
RTX group patients had clearly resectable tumors and a
nodal status according to endorectal ultrasound examina-
tion was N0. Young-age patients and those with higher
risk of disease recurrence (tumor differentiation grade
etc.) with T3-T4 received short RTX. The patients with pre-
treatment nodal status N1 by endorectal ultrasound or
with unresectable T4 rectal tumors composed the long
RTX group. All patients were followed up 42.6 ± 1.9
month after the operation for rectal cancer. The Lithua-
nian Cancer Register supplied the date and cause of death
of those who died during the follow-up period. According
to this information, study subjects were grouped as to
those who survived or failed to survive during follow-up.
Radiotherapy
A SIEMENS "MEVATRON M" 15 MV linear accelerator
was used. Three dimensional conformal radiotherapy was
used for all patients based on a contrast CT scan of the pel-
vis. The four fields „box“ technique was used. For short
RTX group patients, irradiation was given in a dose of 5 Gy
five fractions within five days. Surgical resection was per-
formed within a week after RTX. For long RTX group
patients, irradiation was given in a dose of 50 Gy/5 weeks
with 2 Gy fraction treating 5 days/week. Surgical resection
was performed within six – eight weeks after RTX.
Immunohistochemistry
Paraffin-embedded specimens were sectioned in 3 μm
slices and mounted on glass slides. De-paraffinization and
re-hydration was performed by a slide stainer Varistain
Gemini (ThermoShendon). Then, sections were washed
with distilled water and heated in TRIS/EDTA buffer (pH
9.0) for 8 minutes at 110°C in a Microwave Histoproces-
sor RHS-1 (Milestone, Microwave Laboratory Systems).
Immunochistochemistry was performed by the Shandon
Coverplate system. After blocking endogenous peroxidase
activity, all slides were incubated in the primary antibody
directed towards CD-34 for 1 hour at a dilution of 1:100
in Antibody Diluent (DakoCytomation), followed byBMC Cancer 2009, 9:95 http://www.biomedcentral.com/1471-2407/9/95
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sequential 30 minutes incubations with Advance™ HRP
Link and Advance™ HRP Enzyme (DakoCytomation). The
binding reaction was detected by the Liquid DAB+ Sub-
strate Chromogen System (DakoCytomation). Finally, the
sections were counterstained with Mayer's hematoxylin
(J.T.Baker), and mounted using xylene-based mounting
medium Consul-Mount™ (Shandon).
Evaluation of MVD
Slides stained with anti-CD34 monoclonal antibody were
examined with an Olympus BX 61 light microscope. Sin-
gle endothelial cells or clusters of endothelial cells posi-
tive for CD-34 were considered as a vessel. The presence of
blood cells or fibrin without any detectable endothelial
cells was not sufficient to define a microvessel. Vessels
with muscular walls were not counted. At first, slides were
examined at an original magnification of 4×. Three „hot
spots“(areas with the highest microvessel concentration)
from each slide were identified and these areas were pho-
tographed by a digital Olympus DP-70 camera at an orig-
inal magnification of 10×. The area of this histological
field was 576,207 μm2. Two independent observers with
an Image – Pro AMS 6.0.0 program counted the number
of microvessels in the histological field. MVD (microves-
sel/mm2) was then assessed according to Weidner et al.
[10]. MVD of the specimen was estimated as a mean of
MVD in three histological fields (Figure 1).
Statistical analysis
For statistical analysis, SPSS version 13 (SPSS Inc., Chi-
cago, IL) was used. The Students independent samples t-
test, and ANOVA were used to compare means in groups.
We used the Bonferoni test to compare multiple pairs. It
was used as a precise or asymptomatic significance test
due to the size of the samples. The ROC curves method
was used to establish critical MVD value and later sensitiv-
ity and specificity of this parameter to predict the lethality
issue. Survival curves were estimated by the Kaplan-Meier
method and compared by the Mantel (log rank) test. Prog-
nostic factors of survival were identified by the use of the
Cox proportional hazard model. p < 0.05 was considered
to be statistically significant.
Ethical approval
The study was approved by Kaunas Regional Ethics Com-
mittee for Biomedical Research (protocol No.: 134/2006)
Results
The main clinical data of the patients are summarized in
Table 1. There was no statistically- significant difference
between the groups according to age, sex, tumor T and
death. The tumor T was higher and metastases in lymph
nodes were more frequent in the group that had received
no RTX as compared to the long RTX treatment group.
This phenomenon was due to a radiotherapy downstaging
effect.
Microvessel Density
The mean MVD in the no RTX, the short RTX and the long
RTX groups was respectively 193.0 ± 11.2, 192.5 ± 16.2
and 134.8 ± 7.0 vessel/mm2 (F = 6.726; df = 2; p = 0.002).
The MVD was significantly lower in the samples from
patients who had received the long course of RTX before
operation (Figure 2).
Long course RTX group
There was no significant difference in the MVD according
to gender, T, N, and G in the long RTX group (Table 2).
The patients who underwent long RTX and survived dur-
ing the survey demonstrated significantly smaller MVD in
tumor specimens and had lower lymph node metastatic
rates in comparison to the patients who died during the
survey. The mean MVD was 117.6 ± 5.8 vs. 161.2 ± 11.6
microvessel/mm2, (p = 0.001) and lymph node metastatic
rate was 11.8% vs 45.5% (p < 0.05), respectively (Figure
3, Table 3).
The ROC test was made to discover the MVD cut-off which
displayed a high risk of mortality after long RTX (Figure
4). The cut-off is 130 microvessel/mm2. We obtained
90.9% sensitivity and 70.6% specificity of MVD when the
cut-off is 130.
According to the Kaplan-Meier method and as compared
by the Mantel (log rank) test, the survival period tended
to be longer when the tumor T was lower, there were no
lymph node metastases, the tumor differentiation grade
was better and the patient was female. The survival curve
The "hot spot" (original magnification ×10) Figure 1
The "hot spot" (original magnification ×10). MVD is 
133 microvessel/mm2.BMC Cancer 2009, 9:95 http://www.biomedcentral.com/1471-2407/9/95
Page 4 of 8
(page number not for citation purposes)
also showed a statistically-significant relationship
between microvessel density and the survival period.
When the MVD was lower than a cut off of 130, the sur-
vival period significantly increased (p = 0.001) (Figure 5).
According to the Cox logistic proportional regression
model, the mortality rate is significantly higher if the
MVD is higher than 130 (vessel/mm2) (1953.047; p =
0.002), if the histological grade is moderate/poor
(127.407; p = 0.013), if the tumor is T3/T4 (111.618; p =
0.014), and if the patient is male (17.92; p = 0.034)
adjusted by other variable in model. (Table 4).
Discussion
Angiogenesis plays an important role in tumorogenesis
and metastatic processes. There are few studies done that
investigate the RTX influence on angiogenesis. Aside from
direct tumor cytotoxic effects, RTX may also influence
other physiologic parameters that are known to be impor-
tant in colorectal cancer. In particular, little is known
about the response of angiogenesis to this therapy.
Increased type-IV collagenase activity (MMP-2 and MMP-
9) following preoperative RTX in rectal cancer was
recently discovered [11]. It is of note that these MMP par-
ticipate in angiogenesis [12]. Increased MMP-2 activity
was also reported in colon carcinoma and in osteosar-
coma cell lines after 5 Gy of radiation at short time peri-
ods of up to 24 h. [13]. This evidence shows that RTX may
temporarily increase the invasive potency of the tumor
that leads to micrometastases or split tumor cells at the
time of surgery [14]. According to Baeten et al. [15] RTX
inhibits proliferation of EC despite a high percentage of
residual EC in tumor tissue after prolonged RTX. This sug-
gests a higher sensitivity of non-endothelial cells to RTX
leading to a greater percentage of loss of these cells. MVD
is one of the parameters that assesses the outcome of all
Table 1: Clinical Data of Patient Groups Investigated
Treatment Groups
No RTX
(n = 57)
Short RTX
(n = 16)
Long RTX
(n = 28)
Age M ± SE, years 71.2 ± 1.2 66.0 ± 2.3 67.6 ± 1.6
Sex, %
Male 45.6 43.8 28.6
Female 54.4 56.3 71.4
Tumor, %
pT1/T2 22.8 37.5 35.7
pT3/T4 77.2 62.5 64.3
Lymph node metastases (pN), %
Absent 50.9 56.3 75
Present 49.1 43.7 25
Histological grade (pG), %
Very well/well 66.7 37.5 60.7
Moderate/poor 33.3 62.5 39.3
Mortality Rate, % 42.1 18.8 39.3
Differences of mean ± SE of MVD (microvessel/mm2) in  untreated (no RTX), short term (short RTX) and long term  RTX (long RTX) groups Figure 2
Differences of mean ± SE of MVD (microvessel/mm2) 
in untreated (no RTX), short term (short RTX) and 
long term RTX (long RTX) groups. F = 6.726; df = 2; p* 
= 0.002, p# = 0.034.BMC Cancer 2009, 9:95 http://www.biomedcentral.com/1471-2407/9/95
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Table 2: Microvessel density (MVD) in relation to gender, T, N and tumor differentiation grade in the long term RTX group.
MVD M ± SE (microvessel/mm2) p
Gender
Male 131,46 ± 10.2 0,48
Female 136,07 ± 8.9
Tumor
pT1/T2 145,9 ± 14,2 0,38
pT3/T4 128,56 ± 7,4
Lymph node metastases pN
Absent 134.4 ± 8,8 0,48
Present 135.9 ± 10,1
Histological grade pG
Very well/well 134,4 ± 7,6 0,33
Moderate/poor 135,3 ± 13,7
Table 3: Clinical Data of the Patients who received a long course 
of radiotherapy
Survived
(n = 17)
Deceased
(n = 11)
p
Age M ± SE, years 67.5 ± 1.9 67.8 ± 2.9 0.64
MVD M ± SE, microvessel/mm2 117.6 ± 5.8 161.2 ± 11.6 0.001
Sex, %
Male 35.3 18.2 0.3
Female 64.7 81.8
Tumor, %
pT1/T2 41.2 27.3 0.45
pT3/T4 58.8 72.7
Lymph node metastases (pN), %
Absent 88.2 54.5 0.044
Present 11.8 45.5
Histological grade (pG), %
Very well/well 64.7 54.5 0.59
Moderate/poor 35.3 45.5
Distribution between mean ± SE of MVD (microvessel/mm2)  and survival in untreated (no RTX), short term (short RTX)  and long term RTX (long RTX) groups Figure 3
Distribution between mean ± SE of MVD (microves-
sel/mm2) and survival in untreated (no RTX), short 
term (short RTX) and long term RTX (long RTX) 
groups.BMC Cancer 2009, 9:95 http://www.biomedcentral.com/1471-2407/9/95
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the processes. Our results demonstrate that long RTX pre-
treatment significantly decreased MVD in tumor tissue.
Treatment using short RTX did not change the mean MVD
as compared to tumor samples taken from those receiving
no RTX; the only feature noticeable was that the disper-
sion of MVD was greater in a short RTX group as com-
pared to no RTX group. It is of note that tumor samples
from the short RTX group were taken one week after the
radiation treatment. This suggests that the changes in the
tumor tissue may be subsequent to the cytotoxic effects of
RTX that lead to inflammation that begins in the tumor
straight after RTX [16]. It was demonstrated that RTX up-
regulated expression of adhesion molecules on endothe-
lial cells, and as a result stimulated infiltration of leuko-
cytes into tumor tissue. The increase in expression of EC
adhesion molecules and of leukocyte infiltration after RTX
suggests the activation of a local antitumor reaction [15].
The tumor samples from the patients that received a long
course of RTX were taken 6 – 8 weeks after the RTX. Dur-
ing this period, cytotoxic effects and the inflammatory
reaction induced by radiation treatment in the tumor tis-
sue is diminishing, radiation induced necrotic lesions of
the tumor are repaired by fibrous connective tissue [17].
We might speculate that neoplastic cells have less oppor-
tunity to invade surrounding tissue during surgery when
MVD was decreased. Decreased invasion of neoplastic
cells into surrounding tissues leads to a diminished local
rate of recurrence of the tumor after preoperative RTX. In
spite of this, the overall survival of the patients assigned to
radiotherapy and surgery or assigned to surgery alone is
similar [4]. This phenomenon can be explained by the
development of distal metastases which might have
spread at the beginning of RTX when expression of MMP
and other angiogenic factors are increased [18,19].
In our study, we had limitation in sample size. We had
enrolled all patients underwent surgery for rectal carci-
noma in our surgical department during four years period.
One third of patients underwent emergency operations or
had tumors of another localisation (exclusion criteria).
Another part had incomplete clinical data or unclear out-
come of disease due to missing from follow-up. Some part
of the patients was excluded because of the difficulties
preparing the high quality slides from paraffin-embedded
specimens. These reasons probably could have limited the
reveal of statistically significant relationship between
MVD and other prognostic markers such as tumor T, N, G.
So our findings disagree with the findings of Gallego et al.
They proved a relationship between MVD, G, N and the
prognosis for survival [20,21]. Such a difference may be
explained by the impact of the RTX on tumor angiogen-
esis. We demonstrated that there was a significant differ-
Diagram of ROC curves for patients who received long  course of radiotherapy Figure 4
Diagram of ROC curves for patients who received 
long course of radiotherapy. Area 84.2%; p = 0.003.
Table 4: Multivariate Cox proportional hazard analysis for mortality
Relative risk (B) 95% CI for Exp(B) p
MVD (130 ir >) 1953.047 14.816–257444.0 0.002
Age 0.96 0.864–1.066 0.446
Gender 17.92 1.243–258.432 0.034
Tumor 111.618 2.578–4833.392 0.014
Lymph node metastases 3.34 0.293–38.061 0.331
Histological grade 127.407 2.774–5852.496 0.013BMC Cancer 2009, 9:95 http://www.biomedcentral.com/1471-2407/9/95
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ence in MVD between patients who survived and those
who did not survive during follow-up after combined
treatment of a long course RTX and surgery. Thus MVD
and the overall survival relationship discovered in our
study indicates perhaps that a high MVD after a long
course of RTX may show tumor resistance to radiotherapy
in those tumor samples taken from patients who did not
survive in comparison to those who did survive. This
might indicate tumor resistance to RTX in a subset of
tumors. According to Shia et al., recurrence-free survival
time is better in patients with a fibrotic-type of stromal
response with minimal inflammatory infiltrates [22].
MVD and the overall survival relationship discovered in
our study indicates that high MVD after long RTX may
show a high tumor resistance to radiotherapy.
Conclusion
Our study using MVD in long course RTX reveals a very
defined cut off and appears to have great prognostic
potential. Based on the MVD changes, tumor response to
RTX and individualized treatment could be evaluated.
Further investigations are needed to uncover any changes
in angiogenesis and in the inflammatory reaction during
radiotherapy.
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